ClearPoint Neuro sees record revenue of $7.9 million By Investing.com

ClearPoint Neuro (CLPT) announced a significant increase in its second quarter 2024 financials, showcasing a 32% year-over-year growth with record revenue of $7.9 million. The company made strides across all its growth pillars, notably in biologics and drug delivery, neurosurgery navigation, and therapy and access products, while also expanding its global presence. ClearPoint Neuro’s financial performance was bolstered by a notable rise in gross margin to 63% and a reduction in operational cash burn. The company’s strategic partnerships and FDA accelerated pathway eligibility were key highlights, alongside the upcoming launch of new products and services.

Key Takeaways

• ClearPoint Neuro reported a 32% YoY growth in revenue, reaching a record $7.9 million.
• Gross margin expanded significantly from 53% to 63% compared to the same period last year.
• Operational cash burn was reduced by 39%, with a strong cash position of $32.8 million.
• The company made progress with strategic agreements and expects to become an essential supplier to pharma partners.
• ClearPoint Neuro anticipates long-term growth despite short-term revenue lumpiness due to pharma partnerships.

Company Outlook

• ClearPoint Neuro increased its revenue guidance for the year to $30 million – $33 million.
• They aim to achieve cash flow breakeven by the end of 2025.
• The company expects to reach 100 global sites by the end of 2025 for its neurosurgery navigation systems.

Bearish Highlights

• The company acknowledged short-term revenue lumpiness due to pharma partnerships.

Bullish Highlights

• ClearPoint Neuro activated 14 new customers for its neurosurgery navigation systems in the first half of the year.
• FDA clearance was obtained for the PRISM anchor bolt accessory, with growth expected in disposable laser fibers.
• The company has not seen a negative impact from the health of biopharma companies and continues to see healthy funding in the space.

Misses

• The SmartFrame OR system is still awaiting approval from hospital value committees.

Q&A Highlights

• ClearPoint Neuro is prepared to meet the demand for its ClearPoint system in hospitals with ample supply and additional clinical specialists.
• The company is actively involved in training services related to surgeries, including pump infusions.
• Long-term growth is expected to be driven by milestones and royalties from pharma partners.

In conclusion, ClearPoint Neuro has demonstrated a robust financial performance in Q2 2024, with a clear strategy for continued growth and expansion. The company remains focused on its goal to diversify revenue streams and improve patient care through its innovative products and services.

Full transcript – Clearpoint Neuro Inc (CLPT) Q2 2024:

Operator: Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2024 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company’s plans, prospects and strategies, both preliminary and projected, the size of the total addressable market or the market opportunity for the company’s products and services and management’s expectations, beliefs, estimates or projections regarding future revenue, results of operations or the adequacy of cash and cash equivalent balances to support operations and meet future obligations. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events. For more information, please refer to the company’s annual report on Form 10-K for the year ended December 31, 2023, and the company’s quarterly report on Form 10-Q for the three months ended March 31, 2024, both of which have been filed with the Securities and Exchange Commission and the company’s quarterly report on Form 10-Q for the three months ended June 30, 2024, which the company intends to file with the Securities and Exchange Commission on or before August 14, 2024. All the company’s filings may be obtained from the SEC or the company’s website at www.clearpointneuro.com. And it is now my pleasure to introduce your host, Joe Burnett, Chief Executive Officer. Thank you, Joe. You may begin.

Joe Burnett: Thank you, Morgan, and thank you to all of the investors and analysts on today’s call for being a part of the ClearPoint Neuro vision and journey. Our mission and our priority is to help restore quality of life to patients and their families who are suffering from some of the most debilitating neurological disorders imaginable. In the second quarter of 2024, the entire ClearPoint Neuro team contributed to a record revenue quarter of $7.9 million and in our view, the strongest financial and strategic performance in our history. We made significant progress across all four of our growth pillars including: number one, biologics and drug delivery; number two, neurosurgery navigation; number three, therapy and access products; and number four, achieving global scale. Before we get started, I would like to frame the call by reminding everyone a bit about our history and why these four individual growth pillars are important. When we started our journey here at ClearPoint, we were reliant on just one of these four pillars, which was neurosurgery navigation. We were an MRI navigation company focused on guiding placement of deep brain stimulation lead, and that was about it. As leaders, we’re always looking for that best analogy to help tell our story. Instead of pillars, maybe we should think about a growth engine. And back four years ago, we were essentially a one-cylinder engine. If that cylinder or piston was firing, then we were on the move. If anything happened to that one cylinder, we were stopped in our tracks as we saw at times in our history with COVID case cancellations and limited MRI access. As a team, we set out to improve the performance of this engine. We invested first in catheter and cannulas technology to focus on products for clinical trials sold directly to pharmaceutical partners. We added preclinical services to incorporate our technology into the drug discovery process and to build relationships with pharmaceutical companies well in advance of those first patients being treated. We added laser therapy to control larger portions of the procedure and offer not only the surgical navigation, but also the therapy itself. We realized that MRI access can be a barrier at some hospitals. So we added technology to enable our platform to work not only in the MRI, but also in the operating room using CT as the primary imaging tool. We partnered with technology companies to build out unique software and artificial intelligence modeling capabilities to aid in precisely delivering therapeutics and also grow our installed base. We invested in regulatory submissions to expand access to our technology beyond the United States by growing into the European Union, Asia Pacific and other countries to further support the growing cell and gene therapy market. We now feel that we have successfully added additional cylinders to our company’s growth engine as our year-to-date 2024 results show. The expansion and increased depth of our products and services portfolio will not only help us accelerate our growth, but also allow us to diversify our revenue stream and reach more patients. We are no longer that one cylinder engine, but rather a multicylinder engine that is ready for the next stage of our journey. What we have seen here in the second quarter has been the start of that next phase of ClearPoint where we are now seeing the contribution of all of these cylinders starting to ramp up and to propel us forward. I will now turn the call over to Danilo, our CFO, to review our financial performance in the quarter, after which, I will add some additional detail to our four pillar growth strategy and expectations for the second half of 2024. Danilo?

Danilo D’Alessandro: Thank you, Joe, and good afternoon, everyone. Looking at the second quarter 2024 results, total revenue was $7.9 million for the three months ended June 30, 2024, and $6 million for the three months ended June 30, 2023, which represents 32% growth versus the second quarter of 2023. As a reminder, our revenue is made up of three components: biologics and drug delivery; neurosurgery navigation and therapy; and capital equipment and software. Biologics and drug delivery revenue include sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products. Biologics and drug delivery revenue increased 28% to $4.3 million in the second quarter, up from $3.4 million in 2023. This increase was fueled by $1.3 million or 383% increase in biologics and drug delivery product revenue as multiple pharmaceutical customers progressed in their preclinical and clinical development. The biologics and drug delivery growth was partially offset by $0.4 million decrease in service revenue. Neurosurgery navigation revenue consists of commercial sales of disposable products related to cases utilizing the ClearPoint system, the PRISM laser system or SmartFrame OR. This revenue segment increased 17% to $2.6 million for the second quarter of 2024. The revenue growth is primarily attributable to our new product offerings and our new recent placements. Capital equipment and software revenue consisting of sales of ClearPoint reusable hardware and software and of related services increased 148% to $0.9 million in the quarter from $0.4 million for the same period in 2023 due to an increase in the placement of ClearPoint Navigation capital and software and PRISM laser units. Gross margin for the second quarter of 2024 was 63% as compared to a gross margin of 53% for the second quarter of 2023. The increase in gross margin was primarily due to lower cost for the three months ended June 30, 2024, due to the transition to the new manufacturing facility occurring in 2023 and higher volumes in 2024. In the second quarter of 2024, our operating expenses were $9.7 million compared to $10.3 million for the second quarter of 2023 as we continue to gain operating leverage. Research and development costs were $3.1 million for the three months ended June 30, 2024, compared to $3.6 million for the same period in 2023, a decrease of $0.5 million or 13%. The decrease was due primarily to lower product and software development costs of $1 million as a result of reprioritization of certain research and development initiatives, partially offset by increased personnel costs of $0.3 million and trial cost of $0.2 million. Sales and marketing expenses were $3.8 million for the second quarter compared to $3.5 million for the same period in 2023, an increase of $0.4 million or 10%. This increase was due to additional personnel costs and travel expenses as we expand our commercial reach as we execute on our new product launches and prepare for increased procedural volume. General and administrative expenses were $2.8 million for the second quarter compared to $3.2 million for the same period in 2023, a decrease of $0.4 million or 13%. This decrease was due primarily to lower bad debt expense of $0.7 million, mainly as a result of subsequent recoveries, partially offset by higher personnel costs and share-based compensation of $0.2 million. As of June 30, 2024, our year-to-date operating expenses were about 4% lower than our operating expenses in the same period of the prior year despite growing our revenue 36% in the first half of 2024. With respect to our cash position, as of June 30, 2024, we held cash and cash equivalents of $32.8 million compared to $23.1 million as of December 31, 2023. In line with the prior quarters, we continue to meaningfully reduce our operational cash burn. Our operational cash burn in the second quarter of 2024 was $2.7 million or 47% lower than our operational cash burn in Q2 2023. In the past trailing 12 months, our operational cash burn was $9.5 million. This represents a 46% reduction compared to the corresponding prior 12-month period, that is, from July 2022 to June 2023. With that, I’d like now to turn the call back to Joe.

Joe Burnett: Thanks, Danilo. As mentioned previously, 2024 is off to a great start with a 36% increase in revenue, a 39% reduction in operational cash burn, multiple new product launches, additional long-term pharma partnerships, global expansion of our portfolio and a strong cash position and balance sheet. As always, let’s now break down that progress into our four growth pillars. Starting with pillar number one, biologics and drug delivery. We had a terrific quarter on numerous fronts. Let’s talk about four recent key milestones in our gene and cell therapy business. First, as Danilo mentioned, we saw a significant increase in product sales to pharma partners, representing $1.3 million of growth for the quarter. This is very important as it shows the progression of our partners who are advancing along the regulatory pathway and moving beyond the benchtop where product sales are limited and into large multi-subject GLP preclinical trials and first-in-human clinical trial. Second, we have now seen multiple partners selected for various accelerated FDA pathways designed to speed the clinical trial execution and eventual regulatory approval of these new-to-world cell and gene therapies, often referred to as regenerative therapies. We now have seven partnered programs that have been designated as Fast Track, Priority Review or RMAT, which highlights the importance that the FDA has placed on the entire cell and gene therapy market and the recognition of the life-altering impact these drugs may have to patients. While there is never a guarantee of timeline or approval, it is very reassuring and exciting that the FDA has created these accelerated pathways and that many of our partners have demonstrated significant enough progress and clinical results to be eligible for these programs. In total, if we add together all of the indications that are now included in these expedited programs, the total patient prevalence is measured in the millions of patients globally. Third, we continue to make progress expanding our preclinical services and capacity with the next strategic goal to be GLP ready this year and to commence with our initial GLP studies in 2025. Our team continues to feel confident in the demand for our products and services as well as our team’s unique expertise. We believe in our ability to execute larger studies under GLP compliant procedures and in GLP facilities. This further evolution of our drug delivery business will continue to expand not just the value that we provide, but also help us build even stronger long-term relationships with the pharmaceutical industry. And fourth, speaking of those relationships with pharma, we are excited to share that we have now executed strategic agreements across all of our desired frameworks, proving that we do, in fact, provide unique capabilities that are valued by the cell and gene therapy community. These frameworks also demonstrate our creativity and flexibility on how we can partner based on the needs of each individual pharma partner. We obviously cannot provide detailed pricing or confidential strategic information, but what I can share is that we now have successful signed agreements, representing four different parameters and sometimes a combination of those. For example, number one, co-development where a partner pays a development fee and development milestones to ClearPoint for custom development of a delivery device or software that will be used in their preclinical and clinical trials. Number two, commercial pricing, where a partner intends to provide their drug in a kit with the ClearPoint Neuro technology to simplify the commercial delivery of the product and purchase the devices directly from ClearPoint instead of ClearPoint having to sell the product to hospitals. The commercial pricing is at a premium when compared to the bench and preclinical trial patients. Number three, clinical milestones, whereby ClearPoint Neuro gets a cash payment upon progression of a drug through the regulatory pathway. For example, approval of an IDE or IND study protocol being granted by the FDA or the first patient enrolled in a clinical trial. Importantly, these milestones can happen during the drug discovery and regulatory process and do not have to take place at the very end with commercial approval. And finally, number four, a royalty payment to ClearPoint Neuro based on the drug itself and the commercial sales of that cell or gene therapy, which is delivered using the ClearPoint delivery devices. As a reminder, while not assured, we believe it is likely that these new-to-world drugs will be approved as combination devices with the ClearPoint Neuro cannulas and catheters as was seen in the European Union for the very first neurogene therapy already approved. Our company, therefore, becomes an essential supplier to our pharma partners. As a result, our partners are looking for very long-term agreements, assurances of supply, access to ClearPoint Neuro’s unique intellectual property, redundancy of manufacturing and more. It is this long-term need and partnership that puts us in a position to earn more than just an arm’s length transaction for our products. Moving on to pillar number two, which is neurosurgery navigation, we saw accelerated customer site activations and product sales in the quarter, fueled by both placements of our traditional MRI-guided navigation system as well as the full market release of our SmartFrame OR system designed for use with CT scans. (technical difficulty) Sorry, I think we’re having a couple of technical issues. Can you hear me now?

Operator: Your audio is back, sir.

Joe Burnett: All right, everybody, sorry about the technical issues here. I’m going to go ahead and pick up the script where I left off. So as a reminder, in Q1 of this year, we activated eight new customers, which was by far a new record. In fact, in prior years, opening eight new sites would take a full 12 months, and we accomplished that in the first quarter alone. In Q2, we followed on that success with an additional six customer activations, bringing our total to 14 so far this year. These accelerated placements have helped fuel not only our disposable product sales, which we will talk about in a second, but also capital rental and service sales, which more than doubled versus a year ago. We believe that we have a strong funnel of additional qualified global targets, giving us plenty of shots on goal to achieve 100 global sites by the end of 2025, if not sooner. The SmartFrame OR platform continues to gain traction with additional cases and experience. The early feedback we got from our limited market release gave us enough confidence to move quickly into full market release in concert with the ASSFN meeting in Nashville in June. We currently have the SmartFrame OR going through multiple VAC or VAC committee reviews around the country and expect additional growth here in the second half. I invite you to join our webinar led by Dr. Conner at the University of Oklahoma later this quarter, where he will share his early experiences with the SmartFrame OR product and how it has changed his practice at the university. Next, let’s move on to pillar number three, which is therapy and access products. In the quarter, we obtained FDA clearance for the PRISM anchor bolt accessory, which has opened the door for use of our PRISM laser system with some existing robotics systems at sites that simply prefer to use the robotics navigation in place of our ClearPoint navigation. We have performed first cases using the standardized workflow, which enabled us to move into full market release for the PRISM system. While we do not expect some of these bolt customers to eventually — I’m sorry, while we do expect some of these bolt customers to eventually move to a full ClearPoint navigated workflow for laser, it’s an important first step to offer a solution that fits into their existing workflow so that we are not asking for too much change to their procedure flow on day 1. Similar to the SmartFrame OR, we have a number of evaluations and VAC committee approvals underway. And we expect to see accelerated growth of these disposable laser fibers here in the second half. We do remain somewhat limited to about half of the laser market today as our system is currently only approved for three Tesla (NASDAQ:) scanners. However, there are plenty of target hospitals to keep us busy while we develop the regulatory pathway for the other half of the market, responsible today by 1.5 Tesla scanners, which that approval we anticipate in 2025. We have also made significant progress on our MRI conditional power drill, which we believe will be a powerful complement to our therapy and access product portfolio. This tool in partnership with adeor medical is designed to provide significantly faster access for surgeons than our current hand drill and has the potential to meaningfully reduce procedure time. Our current plan is to submit this product before the end of the year with a commercial introduction sometime in 2025. Now when we report numbers for neurosurgery navigation and therapy, we bucket them together into medical device disposables. As Danilo mentioned, this segment grew 17% in the quarter. It is important to note that this growth was despite $400,000 in services from our brain computer interface partners, which was not repeated here in 2024. Without the brain computer interface service revenue from 2023 and only comparing product sales, the neurosurgery navigation and therapy segment actually grew 42% year-over-year and even grew 34% compared to last quarter alone. Overall, our product sales more than doubled versus a year ago, which has a positive impact on gross margin due to the increased throughput at our factory. Speaking of which, let’s talk about pillar number four, which is in achieving global scale. This was another disciplined quarter from a spending standpoint that saw a 32% revenue growth while keeping operating expenses generally flat. Our gross margin also expanded to 63%, which resulted in an operating cash burn reduction of 47% in the quarter, demonstrating our continued progress towards cash flow breakeven. We continue to believe that a cash flow breakeven quarter by the end of 2025 is possible and feel like we are in a strong cash position today with over $32 million in cash and cash equivalents. Based on the strong first half performance of the team, we feel comfortable increasing our revenue guidance for the year to a new range of between $30 million and $33 million in total revenue, representing growth of between 25% and 38% for the year. With that, we will now open up the call to any questions.

Operator: (Operator Instructions) Your first question comes from Frank Takkinen with Lake Street Capital. Your line is open.

Frank Takkinen: Great. Thanks for taking the questions and congrats on really the great progress really across the entire board. Congrats on the increased guidance. Maybe I wanted to start there. Just curious what’s contemplated versus the low end of the guidance versus the high end of the guidance, obviously, impressive growth profile regardless of where that comes into, but just was curious what you’re thinking about needs to occur for the top end versus low end?

Joe Burnett: Yes. Happy to answer, and thanks for the question, Frank. Yes, by going from $30 million to $33 million, we still leave a large enough window that I think sort of appropriately reflects some of the uncertainty that can happen from quarter-to-quarter. So as an example, like we’ve talked about in the past, we are — I don’t say routinely, but we have in our forecast a number of sort of preclinical services for our pharma partners, where any one of those services or trial support mechanisms could top a $1 million, maybe even $1.5 million today. And based on the timing of our partner, if that were to happen in December versus January of next year, you can see a $1 million to $1.5 million swing. So that’s really the difference. Our view is that we feel like we’ve got a strong forecast to the — certainly to the middle of the guidance that we’ve just adjusted. And the top and bottom range really reflect the timing more on the pharmaceutical side, if anything.

Frank Takkinen: Got it. That’s helpful. And then maybe for my second one, just wanted to ask about the new sites activated. Obviously, Q1 strong at 8%, Q2 strong again at 6%. Maybe talk about that onboarding process, how that has gone with this many new sites being activated in a short period of time, how quickly they can scale up, start ordering product? And then maybe as a last part to that question, any color related to how many of those sites adopted for both classic ClearPoint as well as the laser system?

Joe Burnett: Yes, sure. So as we think about those sites, the majority of the placements of those 14 we’ve seen this year have still been the traditional MRI navigation type. So these were pent-up demand in certain circumstances, some were driven by interest in our laser platform that drove them to bring our navigation system along as well. In some cases, it’s hospitals that are preparing to participate in certain clinical trials down the road in the gene and cell therapy space and are getting the system installed and their staff up and running and familiar with the technology. So really what that mechanism looks like, a hospital never wants to do their very first clinical trial patients and have that also be their very first ClearPoint patient. So what happens more commonly is the hospital is very interested in cell and gene therapy. They see our ClearPoint system as a necessary component to participate and they start their practice by doing simpler biopsy procedures, laser procedures, DBS procedures to become familiar with the technology before they start enrolling these incredibly expensive and important cell and gene therapy trial patients. So that’s really where most of the demand has been. The caveat to that, which is, I think, is an important one, Frank, is that we’re really not seeing much of the impact just yet from SmartFrame OR. So as I mentioned in the prepared remarks, we actively have our system and our economic justification in front of the value committees at various hospitals. But even getting just a disposable system sometimes takes a little bit of time. You have to justify each and every spend the hospital makes these days. So we’re currently going through the process. But what I would say is we haven’t found — we don’t have an instance where a VAC committee has rejected us yet. It’s really a situation where the meeting might only take place once a month or once every two months, and that’s the slowing factor. But once we have — what I say is, once we have approval from a VAC committee either for an MRI-guided system or for the operating room system, we’ve got ample supply, we’ve hired additional clinical specialists that are in training right now to prepare for this demand. And if you look at our inventory levels, they’re still somewhat elevated because we do have products ready to be installed on the capital side. So we can move pretty quickly once we get the green light from the hospital.

Frank Takkinen: Got it. That’s helpful. Thanks, and congrats again.

Joe Burnett: Thanks Frank.

Operator: Your next question comes from Kyle Bauser with B. Riley. Your line is open.

Kyle Bauser: Great. Thanks for taking my questions, and I’ll echo Frank’s comments, a really strong and clean quarter all around, so congrats. As you march towards cash flow positive territory, the biologics business will, of course, be a key contributor. And now as you — as a project matures in this business, you generate more revenues. But can you talk about economies of scale across these projects that — I know you’re focused on a lot of different indications, but presumably, you aren’t having to start from scratch on every new project. So just kind of curious if you could talk a little bit more about how this business will be a key driver of margin expansion?

Joe Burnett: Yes, happy to. I’ll give you a few examples here and there as well. But the biggest benefit that we get, that’s clearly number one is the fact that the same ClearPoint platform and navigation system supports all of these different procedure types that we talked about, whether it’s biopsy or deep brain stimulation or laser ablation or drug delivery, you’re still talking about navigating with our same system and our same software and the disposable elements, the capital elements, even the software workflow is probably 90% to 95% identical across each one of those different things. So as we talked about with Frank’s question, bringing a new site up and running is easy to do because they can practice on simpler procedures like biopsies to prepare them for more complex gene therapy ones. So we get economies of scale on the fact that it’s the same capital equipment and the same navigation headframe that goes in, as well as the training and education of the site. So I think that’s absolutely an important component. The second one is that as we get into these larger preclinical and clinical trials, a hospital is not buying or a pharma company is not buying five or 10 prototype cannulas at this point, but rather they’re purchasing maybe 100, 200 cannulas in navigation system, sometimes all at once, which we can then produce in a batch manner as opposed to doing these small little shipments through sterilization and everything else. So as we get into these larger studies, we absolutely get margin expansion there because we are producing many more products at the same time as part of the same batch. So there’s more examples than that, but those are the two that certainly pop front of mind.

Kyle Bauser: Got it. I appreciate that. And maybe sticking with the biologics business. So you talked about adding new preclinical and clinical trial services in your prepared remarks, you talked about GLP-ready studies, which is great, a big new area. Can you provide a little bit more color here and talk about examples of other services that you could add? And are these mostly based on feedback you’re receiving from your existing customers or just kind of obvious areas to move into?

Joe Burnett: Thank you. Yes. No, I think this has been a place where I think ClearPoint has been somewhat disciplined in our spending approach where we try not to make these large investments until we know that the demand is solid for them, sort of the field of dreams, if you build it, they were come, this is kind of the opposite of it. We’re not building the fields until the team is ready to go. So I’d say we’re very confident that any additional investment we’re making right now into added capacity or added services or new quality control expertise to facilitate a GLP study, all those types of things, we wouldn’t be making that investment now if we didn’t see kind of a clear line of sight, not just for the value or the revenue we can generate as part of the GLP studies, but again, that intimate relationship we will have with the farmer partner to be working with them for the next 10, 15, 20 years throughout the entire drug discovery and commercialization process. So for concrete examples, it’s nothing too much different than we already offer today. It’s really the simple fact that having a GLP compliance facility is something that enables much larger studies that — to your point or to your question before about gross margin, the same is true on these procedures as well, these GLP procedures because again, you’re bashing them, you’re doing many more subjects, sometimes 50, 60 subjects at a time, all over the course of six weeks as opposed to one or two subjects here and there. So I think we’ll be able to see some gross margin expansion driven by this GLP presence as well.

Kyle Bauser: Okay. Got it. I appreciate that. Well, congrats again. I’ll jump back in queue.

Joe Burnett: Thanks Kyle.

Operator: (Operator Instructions) Our next question comes from Matt Blackman with Stifel. Your line is open.

Emily Christy: Hi. This is Emily on for Matt. Congrats on a great quarter, guys.

Joe Burnett: Thanks, Emily.

Emily Christy: Just a couple from me. In terms of kind of zooming out a bit for the health of biopharma companies, company reported this morning, so think some weakness there. I’m just wondering if you’ve seen any of that. Obviously, you’re still signing contracts, but any projects being paused in your pipeline? Anything along those lines?

Joe Burnett: No. I mean if you look back to the start of this year, I’d say, it’s been the opposite. Barring the craziness of Monday earlier this week, I think funding has actually been pretty healthy coming into this particular space. And the simple fact on our end at this point is if you think about the meetings we’re having here at our headquarters in San Diego or meetings we’re having up in San Francisco and in Europe and other places as well, we’ve got a very diversified base of partners, anything from small start-up biotech companies to some of the largest pharmaceutical companies in the world. And obviously, the smaller companies have a little bit more risk there, but these large pharmaceutical companies are very, very cash fluid, let’s call it. So we really have not seen any of those issues. Certainly not like we’ve seen over the last two or three years. This has been the healthiest it’s been in quite some time.

Emily Christy: Okay. Great. And in terms of the biologics partners, you had a couple of kind of advance in their trials to Phase 1, Phase 2. At that point in a trial, aside from the product purchases, the batch purchases that you talked about, are you involved in other kind of service revenue, like regulatory prep, data collection? I know you’ve talked a little bit about that in the past. So I’m just wondering kind of how you’re involved as they are in that stage?

Joe Burnett: Yes. Once they get to that stage, we are not acting today as clinical trial monitors, for example. So that’s something I think if we wanted to build a team around that, we could probably use our sort of unique neuro focus and expertise to be successful there, but it’s not an investment we’re making today, and it’s not something we’ve moved forward with yet. But I’d say, it will be a nice adjacent service that we could go into. The primary role that we played during those studies is the product, as you pointed out, as well as the clinical education and support of the site. There’s two primary components of these procedures. There’s the part that has to do with the drug, which the pharmacy has to transport the drug in, sort out in an appropriate period of time, mix it in certain cases and have it ready for distribution into the patient. And then there’s the surgical procedure itself, which includes the drilling, the pumps that puts the drug in, the cannulas that we make, which — through which the drug is delivered, the navigation that get us to the target, the software that monitors the infusion and tells the surgeon, yes, everything is great, you can go ahead and close the patient, that’s really the part of the ecosystem that we’re trying to control. And we’re getting more involved in training on pumps and everything required the day of the surgery. So if there’s a clinical service that we provide is, again, it’s not monitoring of the trial, but making sure everything the day of the surgery, even if it’s a little bit beyond what the ClearPoint product does, some companies are hiring us to do additional services around pump infusions and things like that. Hopefully, that’s helpful.

Emily Christy: Got it. Yes, that’s great. And then just one last one. In terms of the contract types that you’re now kind of spreading your wings with royalties and such. Is there anything we should think about in terms of revenue cadence for those? I mean, is it going to remove some of the lumpiness with more of the long-term nature of some of those things? How should we be thinking about how the revenue is going to flow with your mix right now?

Joe Burnett: Yes. It’s probably the opposite of removing the lumpiness. If anything, it’s going to create more for a period of time. The good news is, like we said, we’ve got seven of these partners that are in these fast track expedited designations from the FDA. So certain milestones will come. We have some other large pharmaceutical companies that are deep into the GLP process, and will likely be starting their clinical trials here towards the end of 2024 and into 2025. So that’s where you’re going to start to see where one particular quarter, we could get a nice cash milestone which would also be 100% gross margin, for example, and the next quarter, not have one at all. So if you don’t like choppiness quarter-to-quarter, we might frustrate you a little bit. But again, if you look at the 6-month period, 12-month period, things like that, the trend of growth is certainly going to be there along with gross margins, too. So where I think it does start to even out whereas — if we have multiple partners that are all in clinical trials and those are in that Phase 2, Phase 3 standpoint, maybe couple — two, three years from now, that’s where I think we’re just going to have enough volume there that one individual milestone isn’t kind of swing things positive or negative because these milestones or royalties or whatever they happen to be, are going to start to smooth things out.

Emily Christy: Got it. Great. Thank you.

Joe Burnett: Sure. Thanks, Emily.

Operator: At this time, there are no further questions in queue. I’d like to turn the call back over to Mr. Burnett for any further remarks.

Joe Burnett: Thanks again, Morgan. And once again, thank you to everyone interested in being a part of our team’s journey here at ClearPoint. This is an exciting time as we plan for new product and service launches across all four of our growth pillars as well as additional first-in-human trials to initiate in the exciting cell and gene therapy market. We’ve worked very hard to get to this point and are very excited for our entire team, but we are even more excited for the patients that we hope to treat with these new devices and therapies in the near future. The patient and their family are why we are here, and they are ultimately who we are working for. Thank you, and good night.

Operator: This concludes the ClearPoint Neuro second quarter fiscal 2024 earnings call. Thank you for attending and have a great rest of your day.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.